|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Investments in marketable securities | ||||||||||||||||||||
| Finance receivables, net of allowance for credit losses of $1,392 and $1,497, respectively | ||||||||||||||||||||
| Investments in operating leases, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDER'S EQUITY | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholder's equity: | ||||||||||||||||||||
| Capital stock, no par value (100,000 shares authorized; 91,500 issued and outstanding) at June 30, 2026 and March 31, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total shareholder's equity | ||||||||||||||||||||
| Total liabilities and shareholder's equity |
Loading...
